Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP0057 + Olaparib in Advanced Gastric Cancer and SCLC
NCT05411679Phase 2Withdrawn
- Sponsor
- Ellipses Pharma
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Modality
- Polymer-based Nanoparticles
- Countries
- 3
01
Overview
A Phase 2 trial of CRLX101 in gastric cancer (GC), small cell lung cancer (SCLC), sponsored by Ellipses Pharma. Planned start Apr 2023; status: withdrawn.
02
Drugs
CRLX101
03
Conditions
gastric cancer (GC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05411679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411679.